Abstract:We recently read the article by Tian et al with great interest.1 In their research, the authors compared the prognosis of patients with gastric and gastroesophageal junction adenocarcinoma who received perioperative chemoradiotherapy (PCRT) with those who received perioperative chemotherapy (POC) alone. The authors found that the addition of preoperative radiotherapy to POC appears to be associated with an increased risk of death in both the gastric and gastroesophageal junction adenocarcinoma subgroups. However, by reviewing previous studies and conducting an external validation based on the Surveillance, Epidemiology, and End Results (SEER) database, we found some contradicting results. Thus, we believe more caution should be exercised regarding any conclusions that additional radiotherapy increased the risk of death. In the majority of previous studies, a similar prognosis was demonstrated between the PCRT and the POC groups,2-4 a finding that contradicts the results published by Tian et al.1 Furthermore, if we focused on the patient with a T3 to T4 tumor, PCRT might have a positive influence on survival. For example, Stahl et al reported that in the Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET) trial (in which only patients with T3-T4 tumors were included),5 the PCRT group had a significantly improved progression-free survival (hazard ratio [HR], 0.37; P = .01) and the overall survival (OS) also demonstrated a positive trend (HR, 0.65; P = .055). Trying to investigate the result further, we conducted a validation study based on the SEER database, which also is nationwide. We included patients from 2004 through 2014 in the SEER database using the criteria of Tian et al.1 A total of 2201 patients finally were selected in our research, 934 of whom received PCRT and surgery, 336 of whom received POC, and 931 of whom underwent surgery alone. Pairwise 1:1 propensity score matching was performed to compare the survival outcomes among the 3 groups. It was shown that both the PCRT and the POC groups experienced a survival benefit compared with the group treated with surgery alone. However, there was no statistically significant difference noted with regard to the overall survival or cancer-specific survival between the PCRT and the POC groups. We also conducted a subgroup analysis using Cox regression. Within the population of patients with T3 to T4 disease, the PCRT group was found to have significantly improved prognosis compared with the surgery-alone group (HR, 0.44; 95% CI, 0.34-0.58 [P < .001]). Compared with the POC group, the result indicated a survival advantage for PCRT (HR, 0.74; 95% CI, 0.54-1.02 [P = .07]), although statistical significance was not achieved. In addition, it was shown that the PCRT group had a significantly better prognosis than both the POC and surgery-alone groups among patients with T3 to T4 disease and with positive lymph nodes (HRs of 0.65 and 0.44, respectively [P = .02 and P < .001, respectively]). Based on the above evidence, although the contradiction between the study by Tian et al1 and the previous ones remains difficult to explain, it is rational to assume that patients with advanced disease benefit more from radiotherapy. Thus, instead of concluding that radiotherapy may increase the risk, we believe a subgroup analysis is needed. In addition, the description of the tumor stage and patients' characteristics after propensity score matching may facilitate further discussion. No specific funding was disclosed. The authors made no disclosures.

Chemoradiotherapy is Associated with Improved Survival for Resected Pancreatic Adenosquamous Carcinoma

Chemoradiotherapy is Associated with Improved Survival for Resected Pancreatic Adenosquamous Carcinoma: a Retrospective Cohort Study from the SEER Database

Adjuvant Chemotherapy, with or Without Postoperative Radiotherapy, for Resectable Advanced Pancreatic Adenocarcinoma: Continue or Stop?

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis

Efficacy of adjuvant chemoradiotherapy in patients with pancreatic ductal adenocarcinoma after surgery: A real-world study in high-volume pancreatic cancer center.

Improved Prognosis with Induction Chemotherapy in Pathological Complete Responders after Trimodality Treatment for Esophageal Squamous Cell Carcinoma: Hypothesis Generating for Adjuvant Treatment.

Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy

Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection margin, and receiving adjuvant chemotherapy

Adjuvant Therapy with Gemcitabine and Stereotactic Body Radiation Therapy Versus Gemcitabine Alone for Resected Stage II Pancreatic Cancer: A Prospective, Randomized, Open Label, Single-Center Trial.

Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy

Effect of Neoadjuvant Radiotherapy on Survival of Non-Metastatic Pancreatic Ductal Adenocarcinoma: A SEER Database Analysis

Could Adjuvant Chemotherapy Improve Prognosis For Cervical Cancer Patients With Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?

Survival Benefit and Impact of Adjuvant Chemotherapy Following Systemic Neoadjuvant Chemotherapy in Patients with Resected Pancreas Ductal Adenocarcinoma: a Retrospective Cohort Study.

Recurrence and Survival Prediction Models for Receiving Preoperative Chemotherapy Pancreatic Ductal Adenocarcinoma Cancer: A Single-center Retrospective Research

Patients with Gastroesophageal Junction Adenocarcinomas of an Advanced Stage May Benefit from Perioperative Chemoradiotherapy: A Validation Based on the Surveillance, Epidemiology, and End Results Database

[Postoperative Adjuvant Radiotherapy for Pancreatic Carcinoma Patients after Radical Resection].

The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis

Does adjuvant treatment improve survival in R1 resected perihilar cholangiocarcinoma? The risk of overtreatment

Whether Early Stage Pancreatic Ductal Adenocarcinoma Patients Could Benefit from the Post-Operation Chemotherapy Regimens: a SEER-based Propensity Score Matching Study.

Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma